Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 30, 2024 03:00 ET | Source: Janssen Cilag International NV

European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line treatment of patients with EGFR-mutated NSCLC1 In the Phase 3 MARIPOSA...
December 27, 2024 04:24 ET | Source: Research and Markets

The Digital Transformation Market in China, Forecast to 2029: Trends, Demand Drivers, Challenges, and Emerging Opportunities

Dublin, Dec. 27, 2024 (GLOBE NEWSWIRE) -- The "China Digital Transformation - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024-2029)" report has been added to ...
December 20, 2024 12:42 ET | Source: Foresight Ventures VCT plc

Unaudited Half-Yearly Financial Report

FORESIGHT VENTURES VCT PLC(FORMERLY THAMES VENTURES VCT 1 PLC) Unaudited Half-Yearly Financial Report30 September 2024 FINANCIAL HIGHLIGHTS £72.7mTotal net assetsas at 30 September 2024 ...
December 18, 2024 03:58 ET | Source: Janssen Cilag International NV

Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant

The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months...
December 09, 2024 03:00 ET | Source: Janssen Cilag International NV

DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis

New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with daratumumab SC were progression free at 4.5 years1 AURIGA study shows higher rates...
December 08, 2024 12:35 ET | Source: Janssen Cilag International NV

TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy1,2 BEERSE, BELGIUM, Dec. ...
December 08, 2024 11:25 ET | Source: Janssen Cilag International NV

DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma

First subcutaneous anti-CD38 therapy to demonstrate potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study1 ...
December 08, 2024 08:00 ET | Source: SNS Insider pvt ltd

3D Printing Materials Market Size to Reach USD 20.53 Billion by 2032, with Highest CAGR of 24.81% | Exclusive Report by SNS Insider

Austin, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Market Size & Growth Analysis: The SNS Insider report indicates that,“The 3D Printing Materials Market Size was valued at USD 2.8 Billion in 2023 and...
November 26, 2024 07:22 ET | Source: SNS Insider pvt ltd

Patient Flow Management Solutions Market to Reach USD 7.15 Billion by 2032, Driven by the Need for Operational Efficiency in Healthcare – SNS Insider

Austin, United States, Nov. 26, 2024 (GLOBE NEWSWIRE) -- “According to SNS Insider, The Global Patient Flow Management Solutions Market was valued at USD 1.32 billion in 2023 and is projected to...
November 15, 2024 10:12 ET | Source: Janssen Cilag International NV

CHMP recommends RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution...